A Phase Ib, Multi-centre, Open-label Study of a First-in-class Nucleotide Analogue Acelarin (NUC-1031) in Combination With Cisplatin in Patients With Locally Advanced/Metastatic Biliary Tract Cancers

Trial Profile

A Phase Ib, Multi-centre, Open-label Study of a First-in-class Nucleotide Analogue Acelarin (NUC-1031) in Combination With Cisplatin in Patients With Locally Advanced/Metastatic Biliary Tract Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs NUC 1031 (Primary) ; Cisplatin
  • Indications Cholangiocarcinoma; Gallbladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 21 Mar 2018 According to a NuCana media release, the company anticipates reporting further data in 2018.
    • 26 Jan 2018 Planned End Date changed from 1 Sep 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top